Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw an uptick in trading volume on Monday . 5,229,859 shares were traded during mid-day trading, an increase of 3% from the previous session's volume of 5,058,411 shares.The stock last traded at $2.67 and had previously closed at $2.78.
Wall Street Analyst Weigh In
Several research firms have issued reports on IBRX. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd. D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Friday, December 20th.
Check Out Our Latest Research Report on IBRX
ImmunityBio Stock Down 3.6 %
The stock's 50 day moving average price is $4.40 and its 200-day moving average price is $4.60. The stock has a market capitalization of $1.87 billion, a P/E ratio of -2.91 and a beta of 0.86.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of IBRX. Captrust Financial Advisors acquired a new position in shares of ImmunityBio during the third quarter valued at about $41,000. Virtu Financial LLC purchased a new position in shares of ImmunityBio in the third quarter worth about $51,000. Algert Global LLC acquired a new stake in shares of ImmunityBio during the second quarter worth about $86,000. Mirae Asset Global Investments Co. Ltd. boosted its position in ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after buying an additional 4,545 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in ImmunityBio during the 2nd quarter worth approximately $105,000. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
